FDA Accepts Ultragenyx's Gene Therapy Application for Sanfilippo Syndrome, Setting September Decision Date for First-Ever Treatment
The FDA has accepted Ultragenyx's resubmitted BLA for UX111, a one-time gene therapy for the fatal childhood disease Sanfilippo syndrome Type A, with a decision expected by September 19, 2026.
Overview
The U.S. Food and Drug Administration has accepted Ultragenyx Pharmaceutical’s resubmitted Biologics License Application (BLA) for UX111, a one-time intravenous gene therapy designed to treat Sanfilippo syndrome Type A, according to a company announcement on April 2, 2026. The FDA set a Prescription Drug User Fee Act (PDUFA) action date of September 19, 2026, giving the agency roughly five months to render a decision on what would be the first approved therapy for this fatal childhood disease.
Sanfilippo syndrome Type A, also known as mucopolysaccharidosis IIIA (MPS IIIA), is a rare lysosomal storage disorder caused by mutations in the SGSH gene that result in a deficiency of the sulfamidase enzyme. The disease leads to progressive, irreversible neurodegeneration in early childhood, with affected children losing cognitive, language, and motor function over time. Median life expectancy is approximately 15 years, and an estimated 3,000 to 5,000 patients live with the condition in commercially accessible regions. No treatment currently exists.
What We Know
UX111, formally known as rebisufligene etisparvovec, uses a self-complementary adeno-associated virus serotype 9 (AAV9) vector to deliver a functional copy of the SGSH gene via a single intravenous infusion. The therapy is designed to restore sulfamidase enzyme production and reduce the accumulation of heparan sulfate in the brain, the underlying driver of neurological decline.
The BLA was originally submitted and granted Priority Review in February 2025, but the FDA issued a Complete Response Letter in July 2025 citing concerns related to chemistry, manufacturing, and controls (CMC), according to Ultragenyx’s resubmission announcement. Importantly, the CRL did not raise issues with clinical efficacy or safety data. Ultragenyx resubmitted the BLA on January 30, 2026, with comprehensive responses to the manufacturing-related observations.
The application is supported by data from two clinical studies — the Transpher A trial (NCT02716246) and a companion study (NCT04088734) — enrolling a combined 33 patients across five sites in three countries. Long-term follow-up data extending to 8.5 years, with a median follow-up of 4.8 years, were presented at WORLDSymposium 2026 and published in February 2026.
Among 17 younger or earlier-stage patients treated before age two, the data showed a 23.2-point treatment effect on the Bayley-III cognitive raw score compared to natural history (p<0.0001), along with statistically significant improvements in receptive communication (8.1 points, p=0.0076), expressive communication (11.1 points, p=0.0008), and fine motor skills (9.0 points, p=0.0026), as reported in the February 2026 data release. Eight treated children reached a 36-month cognitive developmental age, compared to zero in the natural history cohort.
In older or more advanced patients, 10 out of 10 retained communication abilities and 9 out of 10 maintained independent ambulation at last assessment, well beyond the typical age of functional loss seen in untreated patients, according to the same data release. Cerebrospinal fluid heparan sulfate levels showed a median reduction of 63.98 percent (p<0.001), with 81.5 percent of patients overall achieving at least a 50 percent reduction in the biomarker.
The safety profile was described as acceptable, with liver enzyme elevations being the most frequently reported adverse event. No cases of hypersensitivity, thrombotic microangiopathy, myocarditis, or malignancy were observed across the 33 treated patients, per the long-term data report.
UX111 holds multiple regulatory designations in the United States, including Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Rare Pediatric Disease, and Orphan Drug, as well as PRIME and Orphan medicinal product designations in the European Union, according to the BLA acceptance announcement. If approved, the therapy would be manufactured entirely in the United States at Andelyn Biosciences in Columbus, Ohio and Ultragenyx’s own facility in Bedford, Massachusetts.
What We Don’t Know
Several questions remain ahead of the September decision. The FDA’s review will need to determine whether the resubmitted manufacturing data fully address the CMC concerns raised in the July 2025 Complete Response Letter. While the clinical efficacy data were not at issue, the agency’s manufacturing standards for gene therapy products are particularly stringent given the complexity of viral vector production.
The application seeks accelerated approval based on biomarker endpoints, meaning Ultragenyx would still need to conduct confirmatory studies after any potential approval. The durability of therapeutic benefit beyond the current 8.5-year follow-up window also remains an open question, particularly for children treated at later disease stages.
Pricing has not been disclosed. Gene therapies for rare diseases have drawn scrutiny for costs that can exceed several million dollars per patient, and it is unclear how payers and health systems would approach reimbursement for a one-time treatment targeting such a small patient population.
Analysis
The FDA’s acceptance of the UX111 resubmission is a significant milestone for the Sanfilippo syndrome community, which has had no approved therapeutic options despite decades of awareness of the disease’s genetic basis. The regulatory path has been bumpy — the July 2025 CRL focused on manufacturing issues rather than clinical doubts, which is generally considered a more favorable basis for resubmission than efficacy-related concerns.
The clinical data represent one of the more compelling packages assembled for an ultra-rare pediatric gene therapy. A 23-point cognitive score advantage over natural history, sustained over years of follow-up in a disease where untreated children face relentless decline, is difficult to achieve and difficult to dismiss. The fact that 8 treated children reached a 36-month cognitive milestone that zero untreated children attain underscores the magnitude of the treatment effect.
Ultragenyx’s path also illustrates the evolving regulatory landscape for rare disease therapies. The FDA’s recent plausible mechanism framework, announced in February 2026, could eventually streamline the approval of individualized gene therapies for ultra-rare conditions, though UX111 is proceeding under the existing accelerated approval pathway. The Rare Pediatric Disease designation makes UX111 eligible for a Priority Review Voucher upon approval, adding a financial incentive that has been credited with encouraging rare disease drug development.